Molecular Evidence (rationale) for T cells targeted therapy in iMCD patients:

  • Lymphocyte proliferation, including T cells, angiogenesis and lymphocyte activation (Thomson et al) are three hallmarks of Castleman disease. 

Case Reports of anti-T cell therapy for iMCD patients:

Sirolimus (Rapamycin) is an mTOR inhibitor is thought to block lymphocyte (including T cell) proliferation, angiogenesis (through blocking VEGF expression) and lymphocyte activation. (Thomson et al)

  • To learn more about sirolimus treatment for iMCD, please visit here.

Cyclosporin is a calcineurin inhibitor, which prevents T cell activation, and therefore serves as an immunosuppressant.

  • To see case reports of cyclosporin monotherapy used to treat iMCD patients, please visit here

Clinical Trials targeting T cells in iMCD: 

No clinical trials targeting T cells in iMCD patients have been conducted.